Galena Biopharma (GALE) Gets U.S. Patent Allowance for FBP Peptide Variants

Galena Biopharma, Inc. (Nasdaq: GALE), has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Composition of Matter patent covering Folate Binding Peptide (FBP) peptide variants for use either alone or in combination with the FBP vaccine, E39. Additionally, the patent lays the foundation for additional intellectual property for the use of these variants in a novel vaccination strategy that could be applied to any peptide-based vaccine.

"This patent further supports Galena's overall strategy to develop targeted peptide cancer vaccines to prevent or delay cancer recurrence in early stage, adjuvant patients," said Mark J. Ahn, Ph.D., President & Chief Executive Officer. "Folate targeted therapies are well validated by the industry, and we are excited to continue our work in pursing trials in cancer survivors at high risk for relapse before their disease is detected as metastatic."

Galena's current FBP vaccine, E39, is in an ongoing Phase 1/2 trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. The company has already designed a new Phase 1b trial studying the benefit of these FBP peptide variants in combination with E39 that is awaiting Institutional Review Board (IRB) approval.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• Roots Corporation to go private in C$4.10-per-share deal with Marquee Brands
• Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders